Results showed an increase in the radiation dose to tumors for a majority of participants—increases as high as three times the dose delivered with conventional PRRT. Furthermore, serious side effects and toxicity remained infrequent with the personalized approach.

Additional research is planned for the coming months to determine how personalized PRRT results in improved therapeutic benefits. This includes reduced tumor progression and longer survival.


Beauregard hopes their findings will contribute to modernizing the way PRRT is practiced by proposing an alternative to the one-size-fits-all protocols.

“Owing to the huge success of PRRT, nuclear medicine therapy is re-emerging like never before …Theranostics (therapy + diagnostics) (allows) us to see what we treat with a scan, how much of the treatment is reaching its target (or not); which is not the case of ordinary drugs that are administered blindly,” he said. “This unique feature of nuclear medicine allows us to customize treatments such as PRRT for each individual patient.”

Back to HCB News

Molecular Imaging Homepage